Remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalized patients with COVID-19, a study found. POOL/AFP/File/Ulrich Perrey
The US Department of Health Services announced on Monday it had secured more than 500,000 treatment courses of remdesivir from drugmaker Gilead Sciences for US hospitals until September. “To the extent possible, we want to ensure that any American patient who needs remdesivir can get it.” The drug has received full approval by Japanese health regulators. US approval requires a time-consuming Food and Drug Administration review, but Emergency Use Authorisations can be used in a health crisis when other options are not available.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: